ILIAS Biologics ILIAS Therapeutics

(주)셀렉스라이프사이언스

About Us

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

History

  • 2019

    Apr.Selected as an Export Voucher recipient company
    provided by Korea Trade-Investment Promotion
    Agency.

    Mar.Approved for NIH grant to support Exosome-based
    research.

    Mar.Relocated corp. building to Daedeok Techno valley,
    Daejeon.

    Jan.Established ILIAS Therapeutics, Inc. in New York, US.

  • 2018

    May.Series A Funding (KRW 18.3 billion).

  • 2017

    Nov.Approved for Institut Pasteur Korea occupancy.

    Oct.Approved for Seoul BioHub occupancy.

  • 2016

    Sept.2nd Angel Funding.

    May.Acquired a K-Healthcare Start-up membership
    by Korean Health Industry Development Institute.

    Feb.1st Angel Funding.

    Jan.Certified as Venture company.

  • 2015

    Nov.Approved as a venture company with research facilities.

    Nov.Established corp. in Daejeon, Korea.

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기